Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price target hoisted by equities research analysts at Guggenheim from $800.00 to $1,050.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price suggests a potential upside of 220.00% from the stock’s previous close.
PRAX has been the topic of a number of other research reports. BTIG Research reiterated a “buy” rating and set a $826.00 price objective on shares of Praxis Precision Medicines in a research report on Monday, November 9th. Robert W. Baird raised their target price on Praxis Precision Medicines from $514.00 to $568.00 and gave the stock an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. began coverage on Praxis Precision Medicines in a research note on Friday, October 16th. They issued an “overweight” rating and a $700.00 target price for the company. The Goldman Sachs Group reiterated a “buy” rating and set a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $582.00 price target on shares of Praxis Precision Medicines in a research report on Thursday, September 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $647.68.
Get Our Latest Analysis on Praxis Precision Medicines
Praxis Precision Medicines Stock Performance
PRAX stock opened at $328.13 on Monday. The firm has a 50-day moving average of $289.90 and a two-hundred day moving average of $314.38. Praxis Precision Medicines has a 12 month low of $160.11 and a 12 month high of $392.70. The company has a market cap of $9.17 billion, a price-to-earnings ratio of -25.64 and a beta of 2.85.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, topping the consensus estimate of ($3.54) by $0.31. As a group, equities analysts forecast that Praxis Precision Medicines will post -13.93 earnings per share for the current year.
Hedge Funds Weigh In On Praxis Precision Medicines
Several large investors have recently modified their holdings of PRAX. GAMMA Investing LLC grew its stake in shares of Praxis Precision Medicines by 10.3% in the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after purchasing an additional 31 shares during the last quarter. KBC Group NV raised its stake in shares of Praxis Precision Medicines by 5.8% during the first quarter. KBC Group NV now owns 715 shares of the company’s stock worth $230,000 after purchasing an additional 39 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 0.9% during the third quarter. Nisa Investment Advisors LLC now owns 6,167 shares of the company’s stock worth $1,796,000 after purchasing an additional 56 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in shares of Praxis Precision Medicines by 1.1% during the third quarter. State Board of Administration of Florida Retirement System now owns 6,373 shares of the company’s stock worth $1,856,000 after purchasing an additional 67 shares during the period. Finally, Carl P. Sherr & Co. LLC lifted its holdings in shares of Praxis Precision Medicines by 8.4% during the first quarter. Carl P. Sherr & Co. LLC now owns 972 shares of the company’s stock worth $313,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 67.84% of the company’s stock.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
See Also
- Five stocks we like better than Praxis Precision Medicines
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
